Recent progress in biomimetic nanomedicines based on versatile targeting
strategy for atherosclerosis therapy
Atherosclerosis (AS) is considered to be one of the major causes of
cardiovascular disease. Its pathological microenvironment is
characterized by increased production of reactive oxygen species, lipid
oxides, and excessive inflammatory factors, which accumulate at the
monolayer endothelial cells in the vascular wall to form AS plaques.
Therefore, intervention in the pathological microenvironment would be
beneficial in delaying AS. Researchers have designed biomimetic
nanomedicine (nanomedicine) with excellent biocompatibility and the
ability to avoid being cleared by the immune system through different
therapeutic strategies to achieve better therapeutic effects for the
characteristics of AS. Biomimetic nanomedicine can further enhance
delivery efficiency and improve treatment efficacy due to their good
biocompatibility and ability to evade clearance by the immune system.
Biomimetic nanomedicine based on therapeutic strategies such as
neutralizing inflammatory factors, ROS scavengers, lipid clearance and
integration of diagnosis and treatment are versatile approaches for
effective treatment of AS. The review firstly summarizes the targeting
therapeutic strategy of biomimetic nanomedicine for AS in recent 5
years. Biomimetic nanomedicine using cell membranes, proteins, and
extracellular vesicles as carriers have been developed for AS.